Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Committee Opinion No. 651. American College of Obstetricians and Gynecologists.

Obstet Gynecol. 2015; 126: e143-e146

Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists.

Obstet Gynecol. 2014; 123: 202-216

Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 186. American College of Obstetricians and Gynecologists.

Obstet Gynecol. 2017; 130: e251-e269Lockwood C.J. Moore T. Copel J. et al.Creasey & Resnick’s Maternal-Fetal Medicine: principles and practice. 9th edition. Elsevier, Philadelphia2023 (ISBN 978-0-323-82849-9)Sarayani A. Albogami Y. Thai T.N. et al.

Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.

Am J Obstet Gynecol. 2022; 227: 263.e1-263.e38

Thalidomide-induced teratogenesis: history and mechanisms.

Birth Defects Res C Embryo Today. 2015; 105: 140-156

Thalidomide: the tragedy of birth defects and the effective treatment of disease.

Toxicol Sci. 2011; 122: 1-6

The new pregnancy and lactation labeling rule.

P T. 2016; 41: 713-715

Food and Drug Adminstration (US). Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule.

Fed Regist. 2014; 79: 72064-72103Nelson L.S. Loh M. Perrone J.

Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies.

J Med Toxicol. 2014; 10: 165-172

Federal Food, Drug, and Cosmetic Act (“FDCA”), § 505, 21 U.S.C. § 355 (2020). Available at: https://www.govinfo.gov/content/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapV-partA-sec355.htm#:∼:text=No%20person%20shall%20introduce%20or,with%20respect%20to%20such%20drug.

Risk evaluation and mitigation strategies (REMSs): are they improving drug safety? A critical review of remss requiring elements to assure safe use (ETASU).

Drugs R. 2017; 17: 245-254Choi J.S. Koren G. Nulman I.

Pregnancy and isotretinoin therapy.

CMAJ (Can Med Assoc J). 2013; 185: 411-413

Food and Drug Aministration (US). FDA Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard. 2023. Available at: https://fis.fda.gov/sense/app/ca606d81-3f9b-4480-9e47-8a8649da6470/sheet/dfa2f0ce-4940-40ff-8d90-d01c19ca9c4d/state/analysis. Accessed February 12, 2023.

Seizures. Clinical updates in women’s health care.

American College of Obstetricians and Gynecologists. 2021; XX: 1Bosak M. Słowik A. Turaj W.

Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study.

Epilepsy Behav. 2019; 98: 1-5Beauchamp T.L. Childress J.F.

Principles of biomedical ethics.

8th ed. Oxford University Press, New York2019

Position Statement on the Use of Valproate by Women of Childbearing Potential. American Epilepsy Society. 2021. Available at: https://www.aesnet.org/about/about-aes/position-statements/position-statement-on-the-use-of-valproate-by-women-of-childbearing-potential. Accessed February 12, 2023.

Tracking the states where abortion is now banned. The New York Times, 2023 (Available at:) (Accessed February 14, 2023)LaHue S.C. Gano D. Bove R.

Reproductive rights in neurology—the supreme court's impact on all of us.

JAMA Neurol. 2022; 79: 961-962

Threats to evidence-based care with teratogenic medications in states with abortion restrictions.

JAMA. 2022; 328: 1671-1673